WaveMan
WaveMan · Company
VXRT · Vaxart, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

VXRT Vaxart (VXRT) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0000072444
Quote by TradingView
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
3
13F, latest reported quarter

What the filings say about VXRT

Insiders, 180 days
+$6.5K net bought
1 buyer

Vaxart insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Vaxart, Inc. insiders bought a net $6.5K of stock across 23 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Watson W. Mark
Director
BUY
2026-05-26 SECtraded 2026-05-22
10,000
$6.5K
-37.5%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on Nov 17, 2025.
  • +17.2% median (+17.0% mean) 90-day return after 4 previous buys.
  • The trade is 7.5% of the 134,125 shares held after it.
  • No other insider bought within 30 days.
  • 3 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Watson W. Mark bought about $6.5K of VXRT on May 22, 2026; 3 funds added in the latest 13F quarter.
Watson W. Mark
Director
BUY
2025-12-05 SECtraded 2025-11-17
15,000
$6.2K
+8.1%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Jul 29, 2025.
  • -3.8% median (+8.1% mean) 90-day return after 3 previous buys.
  • The trade is 12.6% of the 119,125 shares held after it.
  • 1 other insider bought within 30 days.
  • 3 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Watson W. Mark bought about $6.2K of VXRT on Nov 17, 2025; 1 other insider bought within 30 days and 3 funds added in the latest 13F quarter.
Watson W. Mark
Director
BUY
2025-12-05 SECtraded 2025-11-17
5,000
$2.0K
+8.1%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Jul 29, 2025.
  • -3.8% median (+8.1% mean) 90-day return after 3 previous buys.
  • The trade is 4.0% of the 124,125 shares held after it.
  • 1 other insider bought within 30 days.
  • 3 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Watson W. Mark bought about $2.0K of VXRT on Nov 17, 2025; 1 other insider bought within 30 days and 3 funds added in the latest 13F quarter.
HERON ELAINE J
Director
BUY
2025-11-21 SECtraded 2025-11-17
23,217
$9.1K
+11.1%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 29.1% of the 79,783 shares held after it.
  • 1 other insider bought within 30 days.
  • 3 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director HERON ELAINE J bought about $9.1K of VXRT on Nov 17, 2025; 1 other insider bought within 30 days and 3 funds added in the latest 13F quarter.
HERON ELAINE J
Director
BUY
2025-11-21 SECtraded 2025-11-17
16,783
$6.9K
+11.1%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 17.4% of the 96,566 shares held after it.
  • 1 other insider bought within 30 days.
  • 3 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director HERON ELAINE J bought about $6.9K of VXRT on Nov 17, 2025; 1 other insider bought within 30 days and 3 funds added in the latest 13F quarter.
23 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 18 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$6.5K over 180 days
more than 65% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
3 funds bought in last quarter
below 99% of Pharma & Biotech
Revenue
+726.7% year over year
more than 95% of Pharma & Biotech
Margin
6.9% net margin
more than 78% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
1.0% of the float short (float per yahoo 2026-10-27) · 4.8 days to cover · settled 2026-10-15
below 73% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch VXRT

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+11.1%12M
-8%+35%+79%+122%2025-102025-122026-022026-042026-062026-082026-10 2025-11-17 · HERON ELAINE J bought $9.1K2025-11-17 · HERON ELAINE J bought $6.9K2026-05-22 · Watson W. Mark bought $6.5K2025-11-17 · Watson W. Mark bought $6.2K2025-11-17 · Watson W. Mark bought $2.0K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns VXRT: institutional holders (13F)

13F holdings, latest reported quarter
Heritage Wealth Advisors
29,655 sh
$17.9K
KINGSWOOD WEALTH ADVISORS, LLC
10,005 sh
$6.1K
Archer Investment Corp
30 sh
$18
LVM CAPITAL MANAGEMENT LTD/MI
25,000 sh
$15
Strive Financial Group ,LLC
2 sh
$1

Congress trades in VXRT

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

VXRT planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Clinical pipeline
10 registered trials, 1 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
5
Phase 1
0 active
3
Phase 2
1 active
2
Multi-phase
0 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · Former PEOOne
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$2.1M
$1.5M
$1.2M
-88%
n/a
2023
$1.9M
$1.4M
$1.2M
-90%
n/a
2022
$3.6M
-$2.1M
$1.9M
-83%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $6.5K bought by insiders over 180 days, 3 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

VXRT financials

Revenue growth
+726.7%
XBRL, annual
Net margin
6.9%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$243.1M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
+9.2%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
$33.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.22x
long-term debt only, 2018-12-31 (91 months older than the period end); equity 2026-06-30
Cash flow to debt
1.92x
TTM operating cash flow over long-term debt only, 2018-12-31 (91 months older than the period end)
Return on equity
+38.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+13.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
+82.0%
operating income after a 1.1% effective tax rate, over long-term debt only, 2018-12-31 (91 months older than the period end) plus average of 2025-06-30 and 2026-06-30 minus cash
Return on capital employed
+57.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Enterprise value
$92.8M
market value at close 2026-10-27 on 2026-07-31 shares, plus long-term debt only, 2018-12-31 (91 months older than the period end), minus cash 2024-09-30
FCF yield
+34.4%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$237.3M$28.7M$7.4M$107.0K
Operating income$18.1M-$66.3M-$83.3M-$114.6M
Net income$16.3K-$66.9K-$82.5K-$107.8M
EPS (diluted)0.07-0.33n/an/a
Operating cash flow$7.7M-$44.8M-$70.5M-$94.8M
Cashn/an/a$34.8M$44.0M
SEC XBRL, fiscal years, as known on 2026-10-28

VXRT Stock Sonar score 6/7 axes

Find similar shapesCompare

VXRT ranks highest on profitability (94th percentile) and risk and compliance (86th), and lowest on institutional and government (28th), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
94
Inputs
  • Return on equity+38.7% · 93 pct, sector of 545
  • Return on assets+13.5% · 90 pct, sector of 691
  • Return on invested capital+82.0% · 95 pct, sector of 45
  • Return on capital employed+57.3% · 99 pct, sector of 576
Financial health
69
Inputs
  • Debt to equity0.22x · 43 pct, sector of 352
  • Cash flow to debt1.92x · 95 pct, sector of 371
Growth
49
Inputs
  • Revenue growth, YoY+726.7% · 95 pct, sector of 505
  • Backlog growth, YoY-93.8% · 3 pct, sector of 40
Insider conviction
60
Inputs
  • Net Form 4 buying (codes P and S), 180d$6K · 64 pct, sector of 429
  • Insider buyers, 180d1 · 56 pct, sector of 438
Institutional and government
28
Inputs
  • Funds adding, latest quarter3 · 1 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$270K · 54 pct, sector of 133
Risk and compliance
86
Inputs
  • Short interest, % of float+1.0% · 80 pct, sector of 816
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+3.1% · 92 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

VXRT filings, in plain words

Are Vaxart insiders buying or selling VXRT?

In the 180 days to 2026-10-28, Vaxart insiders were net buyers, a net $6.5K across purchases and sales reported on Form 4, by 1 buyer.

Read the full summary

In the 180 days to 2026-10-28, Vaxart insiders were net buyers of VXRT, a net $6.5K across purchases and sales reported on Form 4 by 1 buyer. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies